O-015 Association Between Depth of Response (dpr) and Survival Outcomes in RAS-wild-type (wt) Patients with Metastatic Colorectal Cancer (mcrc) Receiving First-Line FOLFOX or FOLFIRI Plus Cetuximab Once-Every-2-weeks in the APEC Study
A. -L. Cheng,G. Cornelio,L. Shen,T. Price,T. -S. Yang,I. -J. Chung,G. -H. Dai,J. -K. Lin,A. Sharma,K. -H. Yeh,B. Ma,A. Zaatar,Z. -Z. Guan,N. Masood,V. Srimuninnimit,T. Yau,F. Beier,S. Chatterjee,R. Lim
DOI: https://doi.org/10.1093/annonc/mdw198.15
IF: 51.769
2016-01-01
Annals of Oncology
Abstract:Introduction: Conventional response parameters (eg, RECIST-defined objective response rate and progression-free survival [PFS]) do not fully recapitulate – either qualitatively or quantitatively – the true impact of targeted therapies on overall survival (OS) in mCRC; thus, novel metrics are required. In patients with RAS-wt mCRC, DpR – one such innovative response metric – has been shown to be induced effectively by first-line chemotherapy plus weekly cetuximab in the CRYSTAL, OPUS, and FIRE-3 studies. The present analysis evaluated the association between DpR and PFS and OS in the RAS-wt population from the Asia-Pacific, multicenter, nonrandomized, phase 2 APEC study.Methods: APEC enrolled 289 patients with KRAS-wt mCRC. Eligible patients received cetuximab once every 2 weeks plus investigator's choice of FOLFOX or FOLFIRI. Study treatment (either all drugs together or maintenance cetuximab in case of early withdrawal of chemotherapy) continued until disease progression, dose-limiting toxicity, or consent withdrawal. RAS status was assessed retrospectively by ion torrent next-generation sequencing on evaluable samples. DpR was defined as the extent of maximal tumor shrinkage (the sum of tumor diameters at the nadir divided by the sum of tumor diameters at baseline) and was expressed as a percentage.Results: Median PFS and OS in the RAS-wt population (n = 167) of APEC were 13.0 and 28.4 months, respectively; the best confirmed objective response rate was 64.7%, and 10.8% of patients underwent curative R0 resections. This study was not designed to formally assess efficacy differences between treatment subgroups; nevertheless, no major differences between patients receiving FOLFOX vs FOLFIRI were detected. There were no unexpected safety findings. The extent of tumor shrinkage was similar between the FOLFOX and FOLFIRI treatment subgroups; among patients whose disease did not progress, tumor size continued to decrease as the duration of treatment increased. 159 patients with RAS-wt mCRC were evaluable for DpR: median DpR was 62.2% (interquartile range [IQR], 39.1%–80.0%) in the overall DpR-evaluable population; in the FOLFOX plus cetuximab (n = 103) and FOLFIRI plus cetuximab (n = 56) treatment subgroups, median DpR was 62.2% (IQR, 40.0%–80.7%) and 62.5% (IQR, 38.1%–79.0%), respectively. The median time to tumor size nadir was 5.9 months (95% CI, 5.6–7.6 months) in the overall DpR-evaluable population; median time to nadir was 5.9 months (95% CI, 5.6–7.6 months) and 7.4 months (95% CI, 5.1–9.2 months) in the FOLFOX and FOLFIRI treatment subgroups, respectively. Notably, there appeared to be an association between the extent of DpR and time to nadir: patients experiencing a deeper response seemed to achieve maximal tumor shrinkage later than patients with a less deep response. Furthermore, the data suggest that there was a relationship between the extent of DpR and PFS/OS (Figure).Conclusion: These findings – obtained using a once-every-2-weeks dosing regimen – compare favorably to earlier subgroup analyses of analogous pivotal studies involving chemotherapy plus weekly cetuximab. DpR seems to be a sensitive indicator of response and is likely to be associated with PFS and OS. The phase 2 APEC study further suggests that patients with RAS-wt mCRC may benefit from an increased duration of treatment with FOLFOX or FOLFIRI plus cetuximab. Introduction: Conventional response parameters (eg, RECIST-defined objective response rate and progression-free survival [PFS]) do not fully recapitulate – either qualitatively or quantitatively – the true impact of targeted therapies on overall survival (OS) in mCRC; thus, novel metrics are required. In patients with RAS-wt mCRC, DpR – one such innovative response metric – has been shown to be induced effectively by first-line chemotherapy plus weekly cetuximab in the CRYSTAL, OPUS, and FIRE-3 studies. The present analysis evaluated the association between DpR and PFS and OS in the RAS-wt population from the Asia-Pacific, multicenter, nonrandomized, phase 2 APEC study. Methods: APEC enrolled 289 patients with KRAS-wt mCRC. Eligible patients received cetuximab once every 2 weeks plus investigator's choice of FOLFOX or FOLFIRI. Study treatment (either all drugs together or maintenance cetuximab in case of early withdrawal of chemotherapy) continued until disease progression, dose-limiting toxicity, or consent withdrawal. RAS status was assessed retrospectively by ion torrent next-generation sequencing on evaluable samples. DpR was defined as the extent of maximal tumor shrinkage (the sum of tumor diameters at the nadir divided by the sum of tumor diameters at baseline) and was expressed as a percentage. Results: Median PFS and OS in the RAS-wt population (n = 167) of APEC were 13.0 and 28.4 months, respectively; the best confirmed objective response rate was 64.7%, and 10.8% of patients underwent curative R0 resections. This study was not designed to formally assess efficacy differences between treatment subgroups; nevertheless, no major differences between patients receiving FOLFOX vs FOLFIRI were detected. There were no unexpected safety findings. The extent of tumor shrinkage was similar between the FOLFOX and FOLFIRI treatment subgroups; among patients whose disease did not progress, tumor size continued to decrease as the duration of treatment increased. 159 patients with RAS-wt mCRC were evaluable for DpR: median DpR was 62.2% (interquartile range [IQR], 39.1%–80.0%) in the overall DpR-evaluable population; in the FOLFOX plus cetuximab (n = 103) and FOLFIRI plus cetuximab (n = 56) treatment subgroups, median DpR was 62.2% (IQR, 40.0%–80.7%) and 62.5% (IQR, 38.1%–79.0%), respectively. The median time to tumor size nadir was 5.9 months (95% CI, 5.6–7.6 months) in the overall DpR-evaluable population; median time to nadir was 5.9 months (95% CI, 5.6–7.6 months) and 7.4 months (95% CI, 5.1–9.2 months) in the FOLFOX and FOLFIRI treatment subgroups, respectively. Notably, there appeared to be an association between the extent of DpR and time to nadir: patients experiencing a deeper response seemed to achieve maximal tumor shrinkage later than patients with a less deep response. Furthermore, the data suggest that there was a relationship between the extent of DpR and PFS/OS (Figure). Conclusion: These findings – obtained using a once-every-2-weeks dosing regimen – compare favorably to earlier subgroup analyses of analogous pivotal studies involving chemotherapy plus weekly cetuximab. DpR seems to be a sensitive indicator of response and is likely to be associated with PFS and OS. The phase 2 APEC study further suggests that patients with RAS-wt mCRC may benefit from an increased duration of treatment with FOLFOX or FOLFIRI plus cetuximab.